PALISADE BIO, INC.
Close on Oct 19, 2026
- Market cap
- $283.25M
- P/E (TTM)
- –
- Dividend yield
- –
About Palisade Bio
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a clinical-stage biopharmaceutical business focused on developing oral phosphodiesterase-4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its primary product candidate, PALI-2108, is an orally delivered therapy engineered for targeted bacterial bioactivation in the lower gastrointestinal tract. Alongside its therapeutic candidates, the business develops biomarker assays to identify individuals who are likely to respond to treatment. Its target patient populations consist of individuals suffering from inflammatory bowel diseases, specifically ulcerative colitis and Crohn's disease, including fibrostenosing Crohn's disease.
The enterprise does not maintain internal manufacturing or testing facilities, relying instead on third-party contract organizations to supply materials for its clinical trials. Its clinical operations take place in Canada, with planned clinical studies in the United States. In addition, the firm holds patent rights and applications across the United States, Japan, and China, and maintains a distribution arrangement covering China, Hong Kong, and Macao. The provided text does not state the location of its headquarters.
Summary of the business section of Palisade Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PALISADE BIO, INC.
- Headquarters
- Carlsbad, CA
- Address
- 7750 El Camino Real, Suite 5200 92009
- Phone
- (858) 704-4900
- Employees
- 100,000, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, New York, NY
Stock & identifiers
- Ticker
- PALI
- Exchange
- Nasdaq
- IPO date
- May 7, 2007
- Shares outstanding
- 174M, Aug 6, 2026
- Public float
- $11.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, May 13, 2024; 1-for-15 reverse, Apr 8, 2024; 1-for-50 reverse, Mar 22, 2023; 1-for-50 reverse, Nov 16, 2022; 1-for-6 reverse, Apr 28, 2021; 1-for-20 reverse, Aug 14, 2019; 1-for-20 reverse, Jul 18, 2019; 1-for-13 reverse, Mar 23, 2017; 1-for-13 reverse, Jan 9, 2017
- SEC CIK
- 1357459
- CUSIP
- 696389402
- ISIN
- US6963894026
- LEI
- 549300W6LIDX3I5XXT34
- EIN
- 52-2007292
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John David Finley | CEO, CFO, Director | 217,739 |
| Mitchell Lawrence Jones | Chief Medical Officer | 94,009 |
| Robert Baltera Jr. | Director | 461,904 |
| Jordan Michael Zwick | Director | 336,904 |
| Donald Allen Williams | Director | 1,512,628 |
| Binxian Wei | Director | 613,355 |
| Emil Chuang | Director | 612,500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Peo | $18.79M | $22.75M | $15.55M | $3 | – |
| FY2024 JDFinley | $813.00K | $691.61K | $581.00K | $2 | – |
| FY2024 Peo | $813.00K | $691.61K | $581.00K | $2 | – |
| FY2023 JDFinley | $1.28M | $1.05M | $328.72K | $11 | – |
| FY2023 Peo | $1.28M | $1.05M | $328.72K | $11 | – |
| FY2022 JDFinley | $613.56K | $460.93K | $249.58K | $8 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“The prevalence of UC is estimated to range from 156 to 291 cases per 100,000 people globally.”
Corporate history
Events identified from SEC filings